logo
logo
  • About us
    • Reig Jofre in brief
    • Strategic pillars
    • Company history
    • Locations
  • Products
    • Product categories
    • Pharmaceutical Technologies
      • Antibiotics
      • Injectable products
      • Others
    • Specialty Products
      • Skin, Hair & Nail Health
      • Joint Health & Pain
      • Women’s Health
      • Respiratory / ENT
      • Pediatrics
    • Consumer Healthcare
    • Healthcare professionals and consumers corner
  • R&D
    • R&D
    • Innovation in Collaboration
    • Pipeline
    • Joint projects
  • Services
    • CDMO services
    • CMO services
  • Investors
    • Information note
    • General information
    • Inside information
    • Other relevant information
    • Former relevant facts
    • Financial information
    • Corporate governance
    • General shareholders’ meetings
    • The share
    • Analysts covering the stock
    • Presentations
    • Webcasts
  • News
    • News and repository
    • Reig Jofre in the media (ES)
    • Subscription center
  • Social Responsibility
  • Contact
    • Contact form
    • Work with us
  • |
  • ES
  • EN

News

Transparency withour stakeholders

  • Show all
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

25 July 2019

Reig Jofre closes the first half of 2019 with a sales growth of 3% and EBITDA of 6%

22 July 2019

Reig Jofre starts the first tranche of the second share buyback program

1 July 2019

Reig Jofre acquires Bioibérica’s portfolio of finished pharmaceutical and nutraceutical products, representing a turnover of € 26M

21 June 2019

Start date of trading for the new shares resulting from the capital increase

17 June 2019

Reig Jofre increases its capital amounting to euros 24 million to finance its expansion plan

17 June 2019

Reig Jofre informs on the result of the increase of the share capital

13 June 2019

Report on the increase of the Company’s share capital

12 June 2019

Start date of the trading of the new shares within its scrip dividend

31 May 2019

Bonus-shares capital increase and new shares to be issued

9 May 2019

Reig Jofre closes the first quarter of 2019 with a sales growth of 6% and net profit of 8%

6 May 2019

Execution of the scrip dividend

30 April 2019

Conditions of the scrip dividend

25 April 2019

Resolutions on 2019 shareholders’ meeting

27 March 2019

Reig Jofre awarded with the Best Business Initiative

25 March 2019

Reig Jofre convenes its 2019 General Shareholders´ Meeting

20 March 2019

Reig Jofre starts marketing its products in South Korea

28 February 2019

Results preview: Year 2018

23 January 2019

Publication schedule for 2019 results

11 January 2019

Ceremony to lay the First Stone of the plant expansion of sterile injectable medicines of Reig Jofre

3 December 2018

Transactions within the share buyback program

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 15

Legal advice – Online store access for employees – RJF connected

© 2020 Laboratorio Reig Jofre

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsRead MoreAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Privacy Preference Center

Privacy Preferences